Talecris Biotherapeutics Holding Corp., a Research Triangle Park, N.C.-based developer of plasma-derived protein therapies, has filed for a $1 billion IPO. It plans to trade on the Nasdaq under ticker symbol TLCR, with Morgan Stanley, Goldman Sachs and J.P. Morgan serving as co-lead underwriters. The company is controlled by Cerberus Management and Ampersand Ventures.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.